The pathogenicity of anti-GAD65 antibodies is related to the recognized antigenic sites, as different epitopes are associated with different diseases, such as stiff person syndrome, cerebellar ataxia, type I diabetes, and thyroiditis (10). This evidence concerns the gene GAD2 and type 1 diabetes mellitus.